Erasca, Inc. (ERAS): Cash & Equivalents
$73.81M
As of 2025-12-31
$42.54M
As of 2026-06-30
-36.2%
3-year compound annual growth
+2.5%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $73.81M | +9.0% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $67.74M | -27.2% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $93.08M | -67.3% | 2025-03-20, Balance as of period end |
| 2022-12-31 | $284.22M | -21.2% | 2024-03-27, Balance as of period end |
| 2021-12-31 | $360.49M | +451.4% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $65.38M | n/a | 2022-03-24, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Erasca, Inc. (ERAS) | 2025-12-31 | $73.81M | +9.0% |
| Ironwood Pharmaceuticals Inc (IRWD) | 2025-12-31 | $215.46M | +143.3% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $112.28M | +61.5% |
| Harrow, Inc. (HROW) | 2025-12-31 | $72.93M | +54.4% |
| Nkarta, Inc. (NKTX) | 2025-12-31 | $39.63M | +42.2% |
| MBX Biosciences, Inc. (MBX) | 2025-12-31 | $75.29M | +52.6% |
| Oric Pharmaceuticals, Inc. (ORIC) | 2025-12-31 | $45.67M | -23.1% |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | $110.64M | -65.4% |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $111.04M | +55.0% |
Compare ERAS, IRWD, TNGX, HROW side by side · Screen every company in Pharmaceutical Preparations ↗